NCT01844791已完成2 期
A Phase IIa Exploratory Study of OCZ103-OS in Combination With Platinum-Gemcitabine Based Doublet First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Overall Response
研究概览
简要总结
The purpose of this study is to investigate the safety and efficacy of the use of OCZ103-OS in combination with Platinum-Gemcitabine based doublet first line therapy in stage IV non-small cell lung cancer (NSCLC) patients.
详细描述
This is a single arm, open label study to investigate the safety and efficacy of the use of OCZ103-OS in combination with Platinum-gemcitabine base doublet first line therapy in stage IV non-small cell lung cancer (NSCLC) patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written Informed Consent;
- •Males or females;
- •18-75 years;
- •Histologically or cytologically confirmed stage IV NSCLC patients that are eligible to platinum-gemcitabine based doublet therapy (M1a and M1b, seventh edition descriptor of the Revised International System for Staging Lung Cancer, adopted by the AJCC.) Patients with a prior diagnosis of stage IIIa or IIIb NSCLC who have progressed to stage IV are also eligible;
- •ECOG performance 0 or 1;
- •One or more tumor lesions measurable by RECIST criteria version 1.1, on CT scan or MRI;
- •Patients with previous radiotherapy as definitive therapy for locally advanced non-small cell lung cancer are eligible, as long as the selected measurable lesions are outside the original radiation therapy port unless there has been demonstrated progression in the lesion. Radiation therapy must have been completed > 4 weeks prior to study entry;
- •Palliative radiotherapy must have been completed > 2 weeks prior to study entry. Concomitant palliative radiotherapy to an existing bone lesion for pain control is allowed;
- •Life expectancy of at least 3 months
排除标准
- •Any prior systemic therapy for recurrent or metastatic NSCLC, except prior neoadjuvant or adjuvant systemic chemotherapy for NSCLC if administered at least 6 months prior to enrolment;
- •Any of the following conditions: Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2; atrial fibrillation of any grade; QTc interval > 450 msec for males or > 470 msec for females or uncontrolled intercurrent illness, e.g. unstable angina; severe coronary disease, ventricular arrhythmias, bradycardia < 50 bpm; a history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia or family history of Long QT Syndrome);
- •Systolic Blood Pressure < 100 mmHg (if deemed clinically significant by the treating physician);
- •Uncontrolled diabetes. Patients with well controlled diabetes, with a HbA1C of less than 7%, on stable hypoglycaemic therapy and diet, are eligible;
- •Clinically significant renal impairment or chronic pancreatitis;
- •History of clinically significant hypoglycemia, with fasting blood glucose < 3 mmol/L;
- •Inadequate baseline organ function as shown by following laboratory values:
- •Hemoglobin < 100 g/L
- •Absolute neutrophil count <1.5 x 10e9/L
- •Platelet count < 100 x 10e9/L
- •Total bilirubin > 1.5 x ULN
- •AST and ALT > 2.5 x ULN or > 5 ULN in the presence of liver metastases
- •Serum creatinine > 1.5 x ULN or calculated creatinine clearance < 60 ml/min
- •To be dependent of oxygen treatment;
- •Active infections requiring antibiotics;
- •A major surgical procedure, open biopsy, or significant traumatic injury within 28 days of beginning treatment, or anticipation of the need for major surgery during the course of the study;
- •Pregnancy or breastfeeding. All women of child-bearing potential must have a negative pregnancy test prior to first receiving protocol therapy;
- •Active alcohol or drug abuse;
- •Known or suspected allergy/hypersensitivity to any agent given in the course of this trial;
- •Any co-morbid condition that in the judgment of the investigator renders the subject at high risk of treatment complication or reduces the probability of assessing clinical effect;
- •Other malignancies diagnosed within the last 5 years with the exception of Basal Cell Carcinoma of the skin;
- •Patients unable to comply with the study protocol and follow-up schedule for any psychological, familial, sociological or geographical reason.
研究组 & 干预措施
OCZ103-OS, Platinum, Gemcitabine
Experimental
OCZ103-OS in combination with Platinum-Gemcitabine as standard of care
干预措施: OCZ103-OS (Drug)
OCZ103-OS, Platinum, Gemcitabine
Experimental
OCZ103-OS in combination with Platinum-Gemcitabine as standard of care
干预措施: Platinum (Drug)
OCZ103-OS, Platinum, Gemcitabine
Experimental
OCZ103-OS in combination with Platinum-Gemcitabine as standard of care
干预措施: Gemcitabine (Drug)
结局指标
主要结局
Overall Response
时间窗: one year four months
To assess the effect of OCZ103-OS on overall objective response in subjects with stage IV non-small cell lung cancer.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard ChemotherapyColorectal CancerNCT01378143Oncozyme Pharma Inc.53
进行中（未招募）
2 期
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaHepatocellular CarcinomaNCT06679985Coherus Oncology, Inc.72
招募中
2 期
Prevention of Ototoxicity in NTM Patients Treated With IV AmikacinOtotoxicity, Drug-InducedNCT05730283Kevin Winthrop105
已完成
1 期
PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC PatientsCarcinoma, Non-Small Cell LungNCT00174356Pfizer39
招募中
2 期
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative ColitisColitis, UlcerativeNCT05076175Bristol-Myers Squibb120